Clinical Trial

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-01; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2025-05-27
Trial Details
NCT Number NCT06915142
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Advanced Malignant Tumour
Enrollment 300 participants
Start Date 2025-04-28
Primary Completion 2026-12 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-26